Clinical trial NCT03717480: Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
Official title: A Phase 2 Study of Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease (GVHD) Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hematologic Malignancy
Keywords: Graft vs. Host Disease
Hematologic Malignancy
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
First posted: 2018-10-24
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant.

The device used to remove the α/βT cells in this study is:

-CliniMACS® TCR α/β Reagent System

Detailed description: Patients who receive an allogeneic (using another person as the donor) stem cell transplant (SCT) are at risk for developing graft-versus-host disease (GVHD).

The word "graft" refers to the donor blood cells that you will receive during the transplant. The word "host" refers to the person receiving the cells. GVHD is a complication of transplantation where the donor graft attacks and damages some of the participant's tissues.

GVHD may occur when the T cells (a type of white blood cell that helps protect the body from infection) from the donor react against normal tissues or organs in the body. There are two basic types of GVHD:

* Acute GVHD often occurs early (generally first 3-6 months after SCT) may affect skin, gastrointestinal tract (stomach and intestines) and liver.
* Chronic GVHD often occurs later (Usually after 3-6 months after SCT) and may affect many organs and significantly diminish quality of life.

To confirm the diagnosis of acute or chronic GVHD, the participant may be asked to have a biopsy (a small sample of the participant's tissue to look at under the microscope) of the skin, gut, or, rarely, the liver.

In this research study, the investigator are investigating a pre-transplant intervention aimed to prevent GVHD by processing the donor product with the Miltenyi CliniMACS TCR α/β Reagent System. The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to the participant. By selectively removing this specific type of T cells from the donor product, the investigators hope to reduce the risk for GVHD without reducing the efficacy of the transplant.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved CliniMACS α/β T cell depletion system for use in the US, but this system is approved by the European Medicines Agency (EMA) and used in Europe

Eligibility criteria: Inclusion Criteria:

* Diagnoses and stage at time of transplant admission:

  * Acute leukemia (AML or ALL or MPAL) in first or subsequent remission
  * Myelodysplastic syndromes (MDS) with \<10% marrow blasts
  * Myeloproliferative neoplasm (MPN) with \<10% marrow blasts
  * CMML with less than 10% marrow blast
  * CML accelerated phase or second or subsequent chronic phase
  * Non-Hodgkin's lymphoma in PR or CR2 or beyond
  * Hodgkin lymphoma in PR or CR2 or beyond
* Age 18-65 years
* Patient has a related or unrelated donor who is 8 or 9 out of 10 match at HLA A, B, C, DRB1 and DQB1, based on allele level typing.
* Patient ECOG performance status 0-2 (Karnofsky ≥60%, see Appendix A)
* Patient deemed to be appropriate candidate for myeloablative conditioning transplantation.
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patient with active HIV infection
* Chronic active hepatitis B infection (HepB surface Ag+ or detectable Hep B viral load)
* Prior allogeneic hematopoietic stem cell transplantation
* Impaired cardiac function- ejection fraction \< 40%
* Impaired pulmonary function- pretransplant FEV1, DLCO \< 50%
* Impaired renal function, based on

  --Serum creatinine \> 2.0 mg/dl
* Impaired liver function unrelated to primary disease, based on

  --ALT or AST \> 3x ULN, or Total Bilirubin \> 2.0mg/dl (with exception for known or suspected Gilbert's disease)
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Women who are pregnant or breast feeding. Women of child bearing potential must have a negative serum pregnancy test at study entry.
* Participants who are receiving any other investigational agents are eligible but such agent must be discontinued before admission for HSCT, and if resumption of investigation agent is planned after HSCT, this must be approved by the study PI.
* Participants with known active CNS disease. CNS disease that has been treated is eligible

Primary outcomes:
measure: Number of Participants With Severe Acute GVHD-free Survival
timeFrame: 100 Days
Secondary outcomes:
measure: Number of Participants With Grades II-IV Acute GVHD
timeFrame: 2 years
measure: Number of Participants With Chronic GVHD
timeFrame: 2 years
measure: Number of Participants With GVHD and Relapse Free Survival (GRFS)
timeFrame: 2 years
measure: Number of Participants With Immunosuppression-free Survival
timeFrame: 2 years
measure: Number of Participants With Hematologic Recovery
timeFrame: 2 years
measure: Number of Participants With Immune Reconstitution
timeFrame: 2 years
measure: Number of Participants With Disease Relapse
timeFrame: 2 years
measure: Number of Participants With Transplant-related Mortality
timeFrame: 2 years
measure: Number of Participants With Organ Toxicity
timeFrame: 2 years
measure: Rates of Infections
timeFrame: 2 years
measure: Number of Participants With Relapse-free and Overall Survival
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Vincent T Ho, MD
role: PRINCIPAL_INVESTIGATOR
References: